

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No 05-1051-B5; (EX04-037-US))**

<b>In the Application of:</b>	)	
<b>Song <i>et al.</i></b>	)	
<b>Serial No.: 10/556,938</b>	)	<b>Examiner: Carlson, Karen C.</b>
<b>Filing Date: February 23, 2007</b>	)	<b>Group Art Unit: 1656</b>
<b>For: RANBP2 as Modifiers of the PTEN/IGF</b>	)	<b>Confirmation No. 7049</b>
<b>Pathway and Methods of Use</b>	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on November 13, 2008, in the above-mentioned application. Applicants submit herewith a petition for a five month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group II, allegedly drawn to a method for identifying PTEN/IGF pathway modulating agents using a nucleic acid encoding RANBP2 which can further comprise a second assay system comprising cultured cells for prosecution on the merits. The claims readable thereon are claims 1-3, 6, 8-12, 16, 18 and 19. Applicants note that only claims 16, 18, and 19 recite the use of a second assay system.

If the Examiner has any questions regarding this response, she is invited to call the undersigned attorney.

Respectfully submitted,

Dated: May 13, 2009

/Anita J. Terpstra/  
Anita J. Terpstra, Ph.D.  
Registration No. 47,132

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-0001